Drugs / antiplatelet thrombolysin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03078257 | Jan 2016 → Nov 2017 | coronary artery disorder | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | antiplatelet thrombolysin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078257 ↗ |
| Action | Inhibit | “GP Ib receptor antagonist” NCT03078257 ↗ |
| Route | Other | “through PV” NCT03078257 ↗ |